Jay Flatley

Jay served as CEO of Illumina, a cutting-edge company in the human health space, for 17 years, and as its executive chair, and later chairman of the board, until 2021. During his tenure as CEO, Jay took Illumina from $1.3 million in sales in 2000 to $2.2 billion in 2015.

In addition to being chairman and acting CEO of Zymergen, Jay serves as a member of the boards of Denali Therapeutics and Coherent, is an advisory board member for the University of California, San Diego’s Moore Cancer Center and serves on the Board of Trustees for The Salk Institute for Biological Studies.

Jay holds both a Bachelor and Master of Science (Hons) from Stanford University, along with a bachelor’s degree from Claremont McKenna College in California.